Skip to main content
SpringerLink
Log in

Immediate identification and management of anthrax essential for optimal outcome

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Inglesby TV, Henderson DA, Bartlett JG, et al., for the Working Group for Civilian Biodefense. Anthrax as a biological weapon: medical and public health management. JAMA 1999; 281(18): 1735–45

    Article  PubMed  CAS  Google Scholar 

  2. Mims CA, Playfair JH, Roitt IM, et al., editors. Medical microbiology. St Loius: Mosby 1993: 314

    Google Scholar 

  3. Williams RP. Bacillus anthracis and other spore forming bacilli. In: Braude AI, Davis LE, Fierer J, editors. Infections disease and medical microbiology. Philadelphia (PA): WB Saunders Co; 1986: 270–8

    Google Scholar 

  4. Lalitha MK, Thomas MK. Penicillin resistance in Bacillus anthracis. Lancet 1997; 349: 1522

    Article  PubMed  CAS  Google Scholar 

  5. Druett HA, Henderson DW, Packman L, et al. Studies on respiratory infection. J Hyg 1953; 51: 359–71

    Article  CAS  Google Scholar 

  6. Penn CC, Klotz SA. Anthrax pneumonia. Semin Respir Infect 1997; 12: 28–30

    PubMed  CAS  Google Scholar 

  7. Simon JD. Biological terrorism: preparing to meet the threat. JAMA 1997; 278: 428–30

    Article  PubMed  CAS  Google Scholar 

  8. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. New Engl J Med 1999; 341(11): 815–26

    Article  PubMed  CAS  Google Scholar 

  9. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994; 266: 1202–8

    Article  PubMed  CAS  Google Scholar 

  10. Pile JC, Malone JD, Eitzén EM, et al. Anthrax as a potential biologic warfare agent. Arch Intern Med 1998; 158: 429–34

    Article  PubMed  CAS  Google Scholar 

  11. Brachman PS. Inhalational anthrax. Ann N Y Acad Sci 1980; 353: 83–93

    Article  PubMed  CAS  Google Scholar 

  12. Leads from the MMWR: human cutaneous anthrax — North Carolina, 1987. JAMA 1988; 260: 616

  13. Bradaric N, Punda-Polic V. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet 1992; 340: 306–7

    Article  PubMed  CAS  Google Scholar 

  14. Edwards MS. Anthrax. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1992: 1053–6

    Google Scholar 

  15. Ibrahim KH, Brown G, Wright DH, et al. Bacillus anthracis: medical issues of biologic warfare. Pharmacotherapy 1999; 19(6): 690–701

    Article  PubMed  CAS  Google Scholar 

  16. Lew D. Bacillus anthracis (anthrax). In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practices of infectious disease. New York: Churchill Livingstone Inc; 1995: 1885–9

    Google Scholar 

  17. LaForce FM. Anthrax. Clin Infect Dis 1994; 19: 1009–14

    Article  PubMed  CAS  Google Scholar 

  18. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. Clin Toxicol 2001; 39(1): 85–100

    Article  Google Scholar 

  19. Alizad A, Ayoub EM, Makki N. Intestinal anthrax in a two-year-old child. Pediatr Infect Dis J 1995; 14: 394–5

    Article  PubMed  CAS  Google Scholar 

  20. US Army Medical Research Institute of Infectious Diseases, Centers for Disease Control and Prevention, and US Food and Drug Administration. Medical Response to Biological Warfare and Terrorism. Gaithersburg, Md: US Army Medical Research Institute of Infectious Diseases, Centers for Disease Control and Prevention, and US Food and Drug Administration; 1998

  21. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR 19 Oct 2001; 50 (41): 889-93

  22. Swartz MN. Recognition and management of anthrax: an update. New Engl J Med. In press

  23. Orent W. Winning a deadly war. Atlanta Journal-Constitution December 13, 1998

  24. Hanna PC, Kruskal BA, Ezekowitz RA, et al. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol Med 1994; 1: 7–18

    PubMed  CAS  Google Scholar 

  25. Anthrax. Centers for Disease Control and Prevention [online]. Available from URL: http://www.bt.cdc.gov/Agent/Anthrax/Anthrax.asp [Accessed 2001 Nov 15]

  26. Food and Drug Administration. FDA talk paper: approval of cipro® for use after exposure to inhalational anthrax [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/AN01030.html [Accessed 2001 Nov 5]

  27. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR 26 Oct 2001; 50 (42): 909-19

  28. American Public Health Association. Anthrax. In: Benenson AS, editor. Control of communicable diseases manual. Washington, DC: American Public Health Association; 1995: 18–22

    Google Scholar 

  29. Cohen JS. Peripheral neuropathy associated with cipro. Annals Pharmacother. In press

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Immediate identification and management of anthrax essential for optimal outcome. Drugs Ther. Perspect 17, 6–11 (2001). https://doi.org/10.2165/00042310-200117240-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117240-00002

Keywords

Search

Navigation